ContraFect

ContraFect EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ContraFect (CFRXQ) as of Oct 19, 2026 is -58.49 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -47.27 M USD — a change of 23.74% (lower).

EBITDA

-58.49 MUSD

YoY

23.74%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ContraFect is 2022 -58.49 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ContraFect was 2021 -47.27 M USD. It decreases by 23.74% lower compared to the previous year.

The ContraFect EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2015
-25.07 M USD
Jan 1, 2016
-33.53 M USD
Jan 1, 2017
-26.56 M USD
Jan 1, 2018
-31.12 M USD
Jan 1, 2019
-27.87 M USD
Jan 1, 2020
-34.24 M USD
Jan 1, 2021
-47.27 M USD
Jan 1, 2022
-58.49 M USD
The ContraFect EBITDA history
YEAREBITDAYoY
-58.49 MUSD+23.74%
-47.27 MUSD+38.05%
-34.24 MUSD+22.86%
-27.87 MUSD-10.44%
-31.12 MUSD+17.17%
-26.56 MUSD-20.79%
-33.53 MUSD+33.75%
-25.07 MUSD+47.99%
-16.94 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ContraFect is -58.49 M USD in 2022.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ContraFect changed from -47.27 M USD to -58.49 M USD, representing a 23.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) ContraFect since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s ContraFect historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ContraFect

All Key Metrics — ContraFect